Solid Biosciences (SLDB) CMO logs RSU vesting and automatic tax-cover sale

Rhea-AI Filing Summary

Solid Biosciences Inc. reported insider equity activity by Chief Medical Officer Gabriel Brooks. Previously granted restricted stock units (RSUs) vested, and each RSU converts into one share of common stock. On the vesting date, 10,937 RSUs were exercised into the same number of common shares at no cash exercise price.

A related sale of common stock was executed solely to cover withholding taxes under a pre‑established durable automatic sales instruction adopted on August 15, 2024. The company notes this sell‑to‑cover transaction was not a discretionary trade by Dr. Brooks. Following these transactions, Brooks directly held 89,466 common shares and 21,876 RSUs.

Insider Trade Summary

10,937 shares exercised/converted

Mixed 3 txns

Insider Brooks Gabriel

Role Chief Medical Officer

Sold 0 shs ($0.00)

Type	Security	Shares	Price	Value
Sale	Common Stock	0	$5.8233	--
Exercise	Restricted Stock Units	10,937	$0.00	--
Exercise	Common Stock	10,937	$0.00	--

Holdings After Transaction: Common Stock — 89,466 shares (Direct); Restricted Stock Units — 21,876 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/18/2026 - 09:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brooks Gabriel

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		M		10,937	A	(1)	95,029	D
Common Stock	02/18/2026		S		0(2)	D	$5.8233(3)	89,466	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/13/2026		M			10,937	(4)	(4)	Common Stock	10,937	$0	21,876	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

2. This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

4. The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

	/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Solid Biosciences (SLDB) report for Gabriel Brooks?

Solid Biosciences reported RSU vesting and related share activity for Chief Medical Officer Gabriel Brooks. 10,937 restricted stock units converted into common shares, and a related sale covered withholding taxes under a pre-set sell-to-cover instruction, rather than a discretionary trade.

Was the Solid Biosciences (SLDB) insider sale by Gabriel Brooks discretionary?

No, the reported sale was not discretionary. It was executed solely to cover withholding taxes following RSU vesting, under a durable automatic sales instruction adopted on August 15, 2024, implementing a sell-to-cover election rather than an opportunistic market trade.

How many restricted stock units vested for Solid Biosciences (SLDB) CMO Gabriel Brooks?

10,937 restricted stock units vested for Chief Medical Officer Gabriel Brooks. Each RSU represents a right to receive one share of Solid Biosciences common stock, and this block converted into the same number of shares in connection with the February 13, 2026 vesting event.

What is the vesting schedule of Gabriel Brooks’ RSUs at Solid Biosciences (SLDB)?

The RSUs were granted on February 13, 2024, and vest over four years. Twenty-five percent of the original RSU grant vests on each anniversary of the grant date until the fourth anniversary, creating a structured, time-based vesting pattern for this equity award.

What shareholdings does Gabriel Brooks have after the reported SLDB Form 4 transactions?

After the reported transactions, Gabriel Brooks directly held 89,466 shares of Solid Biosciences common stock and 21,876 RSUs. The RSUs represent additional potential future shares, subject to the remaining vesting schedule tied to the original February 13, 2024 grant.

At what prices were Solid Biosciences (SLDB) shares sold in the tax-cover transaction?

The weighted average sale price reported was $5.8233 per share. The sale occurred in multiple transactions at prices ranging from $5.23 to $6.14, and detailed breakdowns by price level are available upon request from the reporting person or the company.